By VITL
A 503B pharmacy is an FDA-registered outsourcing facility authorized under Section 503B of the Federal Food, Drug, and Cosmetic Act to compound sterile and non-sterile medications in bulk, without patient-specific prescriptions. Unlike 503A pharmacies, 503B facilities must comply with current Good Manufacturing Practices (cGMP) and are inspected directly by the FDA.
Key takeaways
- 503B pharmacies are FDA-registered outsourcing facilities created by the Drug Quality and Security Act (DQSA) of 2013.
- Drugs compounded in 503B facilities are subject to cGMP standards, the same manufacturing quality framework used by pharmaceutical manufacturers.
- 503B facilities can compound in bulk for office-use stock without individual patient prescriptions; 503A pharmacies cannot.
- Clinics commonly source hormone therapies, sterile injectables, and (subject to bulks-list and shortage status) GLP-1s from 503B pharmacies for in-office administration.
- 503A and 503B serve different needs: 503A for patient-specific custom formulations, 503B for batch-scale office stock.
- Registration with FDA is not a quality determination, and no compounded drug is FDA-approved under either section.
What is a 503B pharmacy? Definition and FDA outsourcing facility overview
A 503B pharmacy is a facility registered with the FDA as an “outsourcing facility” under Section 503B of the Federal Food, Drug, and Cosmetic Act. It is authorized to compound sterile and non-sterile drug products in bulk for healthcare provider office use, no patient-specific prescription required. The statutory definition sits at 21 U.S.C. § 353b(d)(4).
The category didn’t exist a decade ago. It was created by the Drug Quality and Security Act (DQSA) of 2013, passed in the wake of the 2012 New England Compounding Center (NECC) fungal meningitis outbreak that killed 64. Congress wanted a new tier of compounder, one with manufacturer-grade oversight, but operating outside the traditional patient-by-patient prescription model.
FDA’s register lists 97 outsourcing facilities as of August 4, 2026. FDA publishes no total on that page, so the number is a count of the register rather than a figure FDA states. The list is public, refreshed weekly, and worth checking before you sign with any vendor.
The category is growing. FDA’s own end-of-fiscal-year counts run 74 (FY2018), 74 (FY2021), 72 (FY2023), 83 (FY2024), 93 (FY2025), against 97 on the current live list.
FDA is direct about the trade-off facilities accept. Outsourcing facilities “are inspected by FDA according to a risk-based schedule and are subject to increased quality standards,” and separately, “Drugs compounded in outsourcing facilities are subject to current good manufacturing practice (CGMP) requirements.” (FDA, Compounding and the FDA: Questions and Answers)
Here’s what defines the category:
Origin: Created by the DQSA of 2013 after the NECC tragedy.
Legal basis: Section 503B of the Federal Food, Drug, and Cosmetic Act.
Registration: Voluntary to opt in, but mandatory to operate as an outsourcing facility. Facilities re-register annually with the FDA. Registration is not a quality determination — say “registered with FDA,” never “FDA-certified” or “FDA-approved.”
Key distinction: 503B facilities can produce medications without an individual patient prescription, supplying providers with office stock.
Regulator: Direct FDA oversight, versus state boards of pharmacy as the primary regulator for 503A.
Common output: Sterile injectables, ophthalmic preparations, hormone pellets, anesthetic mixtures.
Primary source: FDA, Information for Outsourcing Facilities.
How 503B compounding pharmacies work: registration, oversight, and cGMP standards
Drugs compounded in 503B outsourcing facilities are subject to current Good Manufacturing Practices (cGMP), the same quality framework used by traditional pharmaceutical manufacturers. The facilities are subject to risk-based FDA inspections, adverse event reporting, and product labeling requirements that go well beyond what state boards demand of typical compounders.
This is the part most clinics underestimate. cGMP isn’t a checklist, it’s an entire quality system. In its FY2025 Annual Report to Congress under the Compounding Quality Act, FDA documented 42 inspections of 503B outsourcing facilities, of which 17 were reinspections triggered by noncompliance found in prior inspections. Form 483 observations are not uncommon, and warning letters get published publicly on FDA.gov for anyone to read.
The operational obligations include:
Annual FDA registration and product reporting submitted twice yearly.
cGMP compliance: environmental monitoring, validated processes, stability testing, batch records, and an independent quality unit overseeing release.
Risk-based FDA inspections, high-risk sterile operations are inspected more frequently than lower-risk non-sterile work.
Adverse event reporting obligations under MedWatch.
Labeling requirements: every unit must include a statement that the drug is compounded, plus lot number, beyond-use date (BUD), and storage conditions.
Bulks list constraint: Bulk drug substances must appear on the FDA’s 503B Bulks List, or the brand product must be on the FDA shortage list, to be legally compounded.
Why this matters operationally: cGMP raises both cost and lead time versus 503A. But it produces a product with quality assurance much closer to a manufactured drug. For a clinic injecting dozens of patients per week from a single multi-dose vial, that gap matters.
Primary source: FDA Guidance for Industry: Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B.
503A vs 503B pharmacies: key differences in regulation, scale, and use cases
503A pharmacies compound patient-specific prescriptions under USP 795/797 standards and state board of pharmacy oversight. 503B outsourcing facilities compound in bulk for office use, under FDA inspection, with their drugs subject to cGMP. 503A is better for custom one-off formulations. 503B is better for scaled, repeatable office stock.
The scale gap is stark. Several thousand 503A compounding pharmacies operate in the U.S., against 97 registered 503B outsourcing facilities. Different category, different economics, different role in the supply chain.
Volume tells the same story from the 503A side. The median 503A pharmacy dispenses 350 compounded prescriptions a week, serves 150 different prescribers, and works with 100 unique formulations (Alliance for Pharmacy Compounding, “A Snapshot of Pharmacy Compounding in America 2025–2026,” more than 600 respondents via the Center for Business Research at the University of Mary Washington).
Here’s the side-by-side:
| Dimension | 503A | 503B |
|---|---|---|
| Prescription model | Patient-specific Rx required | Bulk, no patient Rx required |
| Regulator | State boards of pharmacy | FDA direct |
| Quality standard | USP 795, 797, 800 | cGMP |
| Scale | Small-batch, custom | Large-batch, repeatable |
| Pricing | Flexible for unusual strengths and bases | Typically lower per-unit at volume |
| Best for | Personalized HRT, pediatric dosing, allergy testing | In-office injectables, weight-loss programs |
| Risk profile | Product-specific quality variability | Higher regulatory rigor, lower batch variance |
Most growing clinics don’t pick one. They use both. A women’s health practice might fill personalized estradiol creams through a 503A while sourcing office stock from a 503B. For a full decision matrix, see our deeper 503A vs 503B pharmacy comparison.
Primary source: FDA, Compounding and the FDA: Questions and Answers.
Common 503B medications and clinical use cases
Clinics most commonly source hormone replacement therapies, sterile injectables, ophthalmic preparations, and — subject to bulks-list eligibility and shortage status — compounded GLP-1s from 503B outsourcing facilities for in-office administration.
Hormone therapy is the volume anchor of the compounding category, accounting for roughly 36% of compounded volume against 11% for GLP-1s (APC snapshot). That ratio is worth holding onto, because the GLP-1 story is the volatile one.
The most common 503B use cases today:
HRT: Testosterone, estradiol, progesterone, staples in men’s and women’s health clinics.
Ophthalmic injectables and intravitreal preparations for retina specialists.
Aesthetic injectables and tumescent solutions for medspa and surgical settings.
Peptide therapies, subject to bulks list eligibility.
GLP-1s: Semaglutide and tirzepatide, compoundable only while the active ingredient is on the 503B Bulks List or the brand product is on the FDA shortage list.
The shortage-list piece is where most clinics get tripped up, and it is live right now. FDA’s comment period on the proposed 503B bulks-list exclusion for semaglutide, tirzepatide and liraglutide closed June 30, 2026, and the agency can finalize at any time. Nothing is banned today, and nothing is permanently excluded; it remains a proposal. But a medication that is legally compoundable this quarter can stop being compoundable next quarter, with little warning, and that is a supply-continuity problem before it is a regulatory one.
Primary sources: FDA Drug Shortages database and the 503B Bulks List.
How clinics choose a 503B pharmacy (and why most use multiple)
Clinics evaluate 503B pharmacies on FDA inspection history, formulary breadth, pricing, fulfillment speed, and shipping geography. Across the clinics we work with, it’s common to see several active pharmacy relationships running at once, a mix of 503A and 503B, kept in place to cover formulary gaps, manage shortages, and compare pricing.
The evaluation checklist:
Check FDA inspection records and any Form 483 observations or warning letters. FDA’s Inspection Classification Database is publicly searchable by facility, and warning letters are published in full.
Confirm formulary depth for the specific medications, strengths, and dosage forms you actually prescribe, not the marketing catalog.
Evaluate shipping zones, cold chain handling, and fulfillment SLAs. A 2-day pharmacy in your region beats a 5-day national one on cold-chain product.
Compare per-unit pricing, but factor in shipping, minimums, and reorder cadence. Cheapest per vial isn’t cheapest per quarter.
Validate credentialing process and documentation requirements. Some 503Bs take a week. Some take a month.
Recognize the single-point-of-failure problem. Relying on one 503B is operationally fragile — when a facility pauses production due to FDA action or a bulks-list change, your whole formulary goes dark unless you have alternates already credentialed.
The clinics that handle disruption best aren’t the ones with the “best” 503B. They’re the ones with three credentialed 503Bs and a workflow that can switch in a day.
Managing 503B (and 503A) pharmacy relationships with VITL
Here’s the operational reality this guide keeps circling back to: most specialty clinics work with several compounding pharmacies at once. A mix of 503A and 503B. Different logins. Different formularies. Different order forms. Different credentialing requirements. Different invoices.
That’s the problem VITL exists to eliminate.
VITL is a unified ePrescribing platform that consolidates your compounding pharmacy relationships, including FDA-registered 503B outsourcing facilities, into one dashboard. One login. One credentialing flow that works across the network. Real price comparison across pharmacies before you place the order. Batch ordering when you need the same medication and dose for multiple patients. And Amazon-style order tracking your patients can actually see.
We didn’t add features. We removed obstacles. You already have the pharmacy relationships.
We just make them all work together in one place, with better pricing visibility and none of the portal-juggling headache.
If you’re managing multi-location compliance reporting, pre-approved formulary lists, or a direct-to-patient fulfillment model where the clinic holds zero inventory, that’s the workflow VITL was built for.
Beautifully simple ePrescribing. That’s it.
Explore the compounding pharmacy cluster
Going deeper on any of these is the fastest way to get a complete picture:
503A pharmacies: how patient-specific compounding works
503A vs 503B pharmacy: full side-by-side comparison
Choosing a tirzepatide compounding pharmacy
Compounding order tracking for clinics and patients
Clinical pharmacy network connectivity explained
What 503A pharmacy services include
Frequently asked questions
What does 503B mean in pharmacy? 503B refers to Section 503B of the Federal Food, Drug, and Cosmetic Act, which defines “outsourcing facilities” — pharmacies registered with the FDA to compound sterile and non-sterile drugs in bulk for healthcare provider office use, with their compounded drugs subject to cGMP standards.
Is a 503B pharmacy regulated by the FDA? Yes. 503B outsourcing facilities register annually with the FDA, are inspected on a risk-based schedule, report adverse events, and submit product reports twice yearly. Drugs compounded in those facilities are subject to current Good Manufacturing Practices. Registration is not an FDA approval or a quality certification.
What is the difference between 503A and 503B? 503A pharmacies compound patient-specific prescriptions under state board oversight and USP standards. 503B outsourcing facilities compound in bulk for office use under direct FDA oversight, with drugs subject to cGMP, and no individual prescription required.
Can 503B pharmacies compound GLP-1 medications like tirzepatide? Only when the active ingredient is on the FDA’s 503B Bulks List or the brand product is on the FDA drug shortage list. Eligibility changes as shortage statuses and bulks-list decisions are updated, and a proposed exclusion for semaglutide, tirzepatide and liraglutide is currently pending with FDA.
How many 503B pharmacies are there in the U.S.? FDA’s register listed 97 outsourcing facilities as of August 4, 2026. The number moves as facilities register, de-register, or face enforcement action, and facilities that don’t re-register by December 31 are removed from the list on January 1. Check FDA’s published list for the current count.
Do I need a prescription to order from a 503B pharmacy? No individual patient prescription is required, that’s the defining legal difference. 503B facilities supply licensed healthcare providers with office stock for in-office administration to patients.
Why do clinics use multiple 503B pharmacies? No single 503B carries every formulation, and bulks-list changes or FDA enforcement can disrupt supply quickly. Clinics commonly maintain several credentialed relationships to cover formulary gaps, ensure continuity, and compare pricing.
Sources and further reading
FDA, Section 503B of the FD&C Act (fda.gov)
FDA, Registered Outsourcing Facilities list (count as of August 4, 2026)
FDA, Compounding and the FDA: Questions and Answers
FDA Guidance: Current Good Manufacturing Practice — Human Drug Compounding Outsourcing Facilities Under Section 503B
FDA, Annual Report to Congress: Compounding Quality Act, FY 2025
FDA, Drug Shortages database and 503B Bulk Drug Substances List
Alliance for Pharmacy Compounding, A Snapshot of Pharmacy Compounding in America 2025–2026
USP 797 Pharmaceutical Compounding, Sterile Preparations
